These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25483416)

  • 1. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
    Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W
    Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
    Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
    Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
    Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS
    Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
    Yeo W; Chung HC; Chan SL; Wang LZ; Lim R; Picus J; Boyer M; Mo FK; Koh J; Rha SY; Hui EP; Jeung HC; Roh JK; Yu SC; To KF; Tao Q; Ma BB; Chan AW; Tong JH; Erlichman C; Chan AT; Goh BC
    J Clin Oncol; 2012 Sep; 30(27):3361-7. PubMed ID: 22915658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
    Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
    Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
    J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.
    Thomas A; Rajan A; Szabo E; Tomita Y; Carter CA; Scepura B; Lopez-Chavez A; Lee MJ; Redon CE; Frosch A; Peer CJ; Chen Y; Piekarz R; Steinberg SM; Trepel JB; Figg WD; Schrump DS; Giaccone G
    Clin Cancer Res; 2014 Nov; 20(21):5392-402. PubMed ID: 25189481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.
    Liu HB; Mayes PA; Perlmutter P; McKendrick JJ; Dear AE
    Int J Oncol; 2011 May; 38(5):1421-5. PubMed ID: 21253674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
    Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
    BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
    Wang L; Chan CEL; Wong AL; Wong FC; Lim SW; Chinnathambi A; Alharbi SA; Lee LS; Soo R; Yong WP; Lee SC; Ho PC; Sethi G; Goh BC
    Oncotarget; 2017 Jun; 8(25):41572-41581. PubMed ID: 28157715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
    Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
    Goey AK; Sissung TM; Peer CJ; Trepel JB; Lee MJ; Tomita Y; Ehrlich S; Bryla C; Balasubramaniam S; Piekarz R; Steinberg SM; Bates SE; Figg WD
    J Clin Pharmacol; 2016 Apr; 56(4):461-73. PubMed ID: 26313268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.